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IMPORTANCE The 16p11.2 BP4-BP5 duplication is the copy number variant most frequently
associated with autism spectrum disorder (ASD), schizophrenia, and comorbidities such as
decreased bodymass index (BMI).
OBJECTIVES To characterize the effects of the 16p11.2 duplication on cognitive, behavioral,
medical, and anthropometric traits and to understand the specificity of these effects by
systematically comparing results in duplication carriers and reciprocal deletion carriers, who
are also at risk for ASD.
DESIGN, SETTING, AND PARTICIPANTS This international cohort study of 1006 study
participants compared 270 duplication carriers with their 102 intrafamilial control individuals,
390 reciprocal deletion carriers, and 244 deletion controls from European and North
American cohorts. Data were collected from August 1, 2010, to May 31, 2015 and analyzed
from January 1 to August 14, 2015. Linear mixedmodels were used to estimate the effect of
the duplication and deletion on clinical traits by comparison with noncarrier relatives.
MAIN OUTCOMES ANDMEASURES Findings on the Full-Scale IQ (FSIQ), Nonverbal IQ, and
Verbal IQ; the presence of ASD or other DSM-IV diagnoses; BMI; head circumference; and
medical data.
RESULTS Among the 1006 study participants, the duplication was associated with a mean
FSIQ score that was lower by 26.3 points between proband carriers and noncarrier relatives
and a lower mean FSIQ score (16.2-11.4 points) in nonproband carriers. Themean overall
effect of the deletion was similar (–22.1 points; P < .001). However, broad variation in FSIQ
was found, with a 19.4- and 2.0-fold increase in the proportion of FSIQ scores that were very
low (40) and higher than themean (>100) compared with the deletion group (P < .001).
Parental FSIQ predicted part of this variation (approximately 36.0% in hereditary probands).
Although the frequency of ASDwas similar in deletion and duplication proband carriers
(16.0% and 20.0%, respectively), the FSIQ was significantly lower (by 26.3 points) in the
duplication probands with ASD. There also were lower head circumference and BMI
measurements among duplication carriers, which is consistent with the findings of previous
studies.
CONCLUSIONS AND RELEVANCE Themean effect of the duplication on cognition is similar to
that of the reciprocal deletion, but the variance in the duplication is significantly higher, with
severe andmild subgroups not observed with the deletion. These results suggest that
additional genetic and familial factors contribute to this variability. Additional studies will be
necessary to characterize the predictors of cognitive deficits.
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T he 600-kilobase (kb) break points 4 and 5 (BP4-BP5)16p11.2 deletion and duplications (chr16; 29.6-30.2megabase) are among themost frequent genetic causes
of autism spectrum disorder (ASD), schizophrenia, and other
neurodevelopmental disorders.1-5 These reciprocal copynum-
ber variants (CNVs) are associated withmirror phenotypes of
obesity and being underweight and with increased and de-
creased global and regional brain volumes indeletion anddu-
plicationcarriers, respectively.6-8Previousstudies5,9havedem-
onstrated that ASD is diagnosed in approximately 18% of
deletion carriers and that this CNV affects global cognition by
shifting the IQ approximately 2 SDswithout altering the vari-
ance. To our knowledge, such studies have not been con-
ducted for the reciprocal duplication. Akin to duplications of
other genomic regions, case series10-18 have reported variable
expressivity and suggested incomplete penetrance; how-
ever, incomplete penetrance was recently ruled out after re-
callingcarriers identified inunselectedpopulations.19Thisphe-
notypic variability and the limited available data underscore
the need to systematically characterize the clinical impact of
the duplicationwith standardized assessments in large num-
bers of carriers.
The goal of this study was to characterize and elucidate
the effects of the 16p11.2 duplication on cognitive, behav-
ioral, medical, and anthropometric traits and to understand
the specificityof these effects by systematically comparing re-
sults in duplication carriers and reciprocal deletion carriers,
whoare also at risk forASD.To this end,weestablished, to our
knowledge, the largest cohort of duplication (n = 270) andde-
letion (n = 390) carriers todate fromthe 16p11.2Europeanand
Simons Variation in Individuals Project (Simons VIP) consor-
tia and the Cardiff University Experiences of Children With
CopyNumberVariants (ECHO)Study.Wepresenthere thenatu-
ral history andphenotypic variation among the 16p11.2 dupli-
cation carriers and compare their results with those of their
intrafamilial control individuals (n = 102) and of individuals
with the reciprocal 16p11.2 deletion ascertained by similar
methods.
Methods
Patients
This studywas reviewed and approved by the ethical commit-
tee or institutional review board for the European consortium
(http://www.cer-vd.ch/).Written informed consent and,when
appropriate,assentwereobtainedfromtheparticipantswhoun-
derwent full clinical assessments.
Inclusion and Exclusion Criteria
This study describes only the proximal 600-kb recurrent
16p11.2CNVdelineatedbyBP4andBP5(29.6-30.2–Hg19).5Car-
riers have the same BP4-BP5 duplication (or deletion). Con-
trol participants were familymembers of the carriers who do
not carry the 16p11.2 duplicationor deletion. Individualswith
anadditionaldeleteriousCNVwereexcluded.DeleteriousCNVs
were defined as (1) a known recurrent genomic disorder, (2) a
CNVencompassing apublished critical genomic regionordis-
rupting a gene that is a known cause of neurodevelopmental
disorders, or (3) rare (<1of 1000)and large (>500kb)CNVs.The
percentagesof additionaldeleteriousCNVswerecomparedbe-
tween duplication probands and deletion probands similarly
ascertained on the basis of a neurodevelopmental disorder
(eMethods in the Supplement). Ascertainment is detailed in
eTable 1 and the eMethods in the Supplement. Data were col-
lected from August 1, 2010, to May 31, 2015.
Cognitive Functioning, Psychiatric,
and Behavioral Assessments
Phenotypicevaluations for theSimonsVIPparticipantsandthe
16p11.2 European Consortium were performed as previously
reported.5TheWechslerAbbreviatedScalesof Intelligencewas
used to assess IQ for the ECHO Study participants.
Statistical Analysis
Datawere analyzed from January 1 to August 14, 2015.We ex-
amined differences in the Full Scale (FSIQ), Verbal (VIQ), and
Nonverbal (NVIQ) IQs and z scores for bodymass index (BMI)
(calculatedonheightandweight) andheadcircumference (HC)
between 16p11.2 duplication carriers and their noncarrier fa-
milial controls. The IQ values were derived from age and
developmentally appropriate standardizedmeasures (Differ-
ential Ability Scales,20 Mullen Scales for Early Learning–AGS
Edition,21 and Wechsler Abbreviated Scales of Intelligence22).
Cognitivemeasuresare standardized toamean (SD)of 100 (15),
with higher scores indicatingmore developed cognitive abili-
ties. For participants performing out of normative range on
instruments,wegenerated ratio IQscoresbasedonsubtest raw
score age equivalencies (mental age/chronological age × 100)
so that an accurate IQ estimate was established for each par-
ticipant. The BMI z scores were estimated based on age and
sex norms, andHC z scoreswere estimated based on age- and
sex-normed orbitofrontal HCmeasurements obtained during
laboratory visits.
Carriers were stratified into the following 3 groups: pro-
bands, pediatric carrier relatives (<18 years of age), and adult
carrier relatives (≥18 years of age). These groups were com-
paredwithnoncarriers.Wealso compareddifferences in phe-
notypesbetweenprobandswhose inheritance status (denovo
and inherited) was documented and their noncarrier familial
controls. The same analyses were performed with the dele-
tion carriers and their noncarrier familial controls.
We used linear mixed models to compare differences in
phenotypes between carrier or inheritance groups while ac-
counting for correlatedmeasureswithin families (familial clus-
tering) to estimate the effect of the 16p11.2 duplication or de-
letiononthephenotype.Thegroupdifferenceswerecontrolled
for by study cohort (European vsUnited States), age, and sex.
Additional contrasts were included for multilevel categorical
variables to allow for pairwise comparison among all levels of
the variable. To examinewhether the group differenceswere
drivenbyotherdiagnostic factors,additional linearmixedmod-
elswere fittedbyaddingASD, seizurediagnosis, and,whenap-
plicable, NVIQ to the existing models as covariates.
We used the Levene test23 to assess equality of variance
and theFisher exact test to assess the association betweenbi-
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nary variables. To study the longitudinal trendof BMI andHC
valuesamongdeletionandduplicationgroups,wegroupedthe
data points into age windows. We used linear mixed models
to compare the mean values of BMI and HC of carriers to the
populationmeansor familial controls (if available) at each time
window.All statistical analyseswereconductedusingSAS (ver-
sion 9.4; SAS Institute Inc) and R (R Core Team) software.
Results
Descriptive statistics forour 1006studyparticipantsare shown
in Table 1 and Table 2. We first compared duplication carriers
with their familial controls for cognition, neurologic find-
ings, psychiatric symptoms, BMI, and HC and then per-
formedsimilarcomparisonsbetweendeletioncarriersandtheir
familial controls.
Global Cognitive Functioning
The mean FSIQ across the 270 duplication carriers was 78.8.
Forty-seven of 154 carriers (30.5%) met criteria for intellec-
tual disability. When controlling for cohort, age, and sex, the
FSIQ was significantly lower in duplication carriers com-
paredwith intrafamilial controls (18.0points;P < .001;Table3).
The largest effectwasobserved inprobands (decrease inmean
FSIQ, 26.3 points) followedbypediatric and adult carrier rela-
tives (decreases, approximately 16.2 and 11.4 points, respec-
tively) relative to intrafamilial controls. When controlling for
the same covariates, the effect of the reciprocal deletion was
similar,withameandecrease incarriersof22.1points (P < .001;
eTable 2 in the Supplement) in FSIQ compared with intrafa-
milial controls.
The effect of cohort on FSIQ was the same in both CNV
groups, with significantly lower FSIQ in the European vs the
US cohort (by 13.3 points in the duplication group and 13.9
points in thedeletiongroup;P < .001).TheeffectsofbothCNVs
on FSIQ, VIQ, and NVIQ remained similar after additionally
controlling for ASD and seizures (eTables 3-8 in the Supple-
ment), which were associated with IQ in the duplication but
not thedeletion groups (see theNeurologic Findings andPsy-
chiatric Symptoms subsections in this Results section).
Variability of the Effect on Global Cognition
The variance of FSIQ in duplication carriers was significantly
higher thanobservedindeletioncarriers (Levenetest,P < .001).
We founda 19.4-foldexcess (Fisher exact test,P < .001) of very
low FSIQ (≤40; 15 of 154 [9.7%]) in the duplication compared
with the deletion carriers (1 of 200 [0.5%]) and a 2.0-fold en-
richment (Fisher exact test, P = .01) of the duplication carri-
ers greater than thepopulationmeanFSIQ comparedwithde-
letion carriers (>100; 30 of 154 [19.5%] vs 20 of 200 [10.0%])
whowereascertainedby thesame investigatorsusing thesame
methods (Figure 1). The European and US duplication co-
horts contributed (albeit not equally) to the lower- andhigher-
functioning participants (eFigures 1 and 2 in the Supple-
ment). The largevarianceofFSIQamongduplicationprobands
was not driven by cohort, the presence of ASD, seizure status,
or HC (eFigure 2 in the Supplement).
Table 1. Sex, Age, and Inheritance Status by 16p11.2, Cohort, and Carrier Group
Cohort by Carrier Group
No. of
Participants
Male,
No. (%)
Age,
Mean (SD), y
16p11.2 Inheritance, No. (%)a,b
De Novo Inherited
16p11.2 Duplication
European
Proband carrier 97 54 (55.7) 24.2 (21.9) 14 (14.4) 31 (32.0)
Pediatric carrier relative 6 3 (50.0) 5.7 (3.4) 0 6 (100)
Adult carrier relative 24 13 (54.2) 41.9 (12.0) 0 6 (25.0)
Noncarrier 12 5 (41.7) 28.8 (14.8) 7 (58.3) 4 (33.3)
United States
Proband carrier 83 50 (60.2) 9.1 (8.8) 17 (20.5) 44 (53.0)
Pediatric carrier relative 17 8 (47.1) 7.3 (4.4) 0 17 (100)
Adult carrier relative 43 21 (48.8) 40.3 (10.2) 3 (7.0) 13 (30.2)
Noncarrier 90 38 (42.2) 28.9 (17.8) 28 (31.1) 57 (63.3)
16p11.2 Deletion
European
Proband carrier 170 101 (59.4) 16.5 (15.9) 57 (33.5) 49 (28.8)
Pediatric carrier relative 21 13 (61.9) 10.6 (3.5) 0 19 (90.5)
Adult carrier relative 31 11 (35.5) 38.1 (8.9) 0 6 (19.4)
Noncarrier 33 15 (45.5) 30.5 (16.2) 21 (63.6) 6 (18.2)
United States
Proband carrier 147 86 (58.5) 7.6 (4.9) 87 (59.2) 18 (12.2)
Pediatric carrier relative 11 6 (54.5) 8.6 (3.9) 2 (18.2) 9 (81.8)
Adult carrier relative 10 5 (50.0) 39.0 (5.0) 1 (10.0) 0
Noncarrier 211 90 (42.7) 28.9 (14.9) 183 (86.7) 12 (5.7)
a For noncarriers, the value
represents the number from
families with proband carriers
having de novo, inherited, or
unknown status.
b Inheritance status was unknown for
some carriers. Percentages are
based on the total number of
carriers and not only those with
known inheritance status.
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Another factor underlying increased variation in IQ may
have been additional undetected genetic variants. When we
combined the European, Simons VIP, and Signature Genom-
icsLaboratoriesdatasets (described ineMethods in theSupple-
ment), the odds of an additional deleterious CNV were 2.5-
fold higher in duplication compared with deletion carriers
ascertained for neurodevelopmental disorders (P = .006)
(eMethods and eTable 9 in the Supplement). Themedian size
and the mean number of genes included in additional CNVs
are similar for 16p11.2 deletion and duplication carriers
(eFigure 3 in the Supplement).
Global Cognition of De Novo and Inherited
Duplication Carriers
TheFSIQ,NVIQ,andVIQwerenotsignificantlydifferent inpro-
bandswith de novo vs inherited duplications butwere signifi-
cantly greater in probandswith de novo vs inherited deletions
(eTables 10 and 11 in the Supplement). In families with inher-
itedduplications,approximately36.0%oftheIQvarianceinpro-
bands was accounted for by the IQ of the transmitting parent
(eFigure 4 in the Supplement). Too few de novo carriers were
available for this analysis (n = 13). For deletion carriers, less of
the variability was explained by parental IQ (11.0% for inher-
ited and de novo cases; eFigure 4 in the Supplement).
Neurologic Findings
Epilepsy was reported in 35 of 180 of duplication probands
(19.4%) and 2 of 90 of their carrier relatives (2.2%) (eTable 12
in the Supplement). We found a broad spectrum of severity
ranging from benign focal epilepsy to severe epileptic syn-
dromes,with focal epilepsies being themost frequent type (16
of 37 [43.2%]). In the reciprocal deletion group, the fre-
Table 2. Mean IQ and Anthropometric Measures by 16p11.2 Status, Cohort, and Carrier Group
Cohort by
Carrier Group
FSIQ NVIQ VIQ
z Score
BMI HC
No. of
Participants Mean (SD)
No. of
Participants Mean (SD)
No. of
Participants Mean (SD)
No. of
Participants Mean (SD)
No. of
Participants Mean (SD)
16p11.2 Duplication
European
Proband
carrier
30 63.9 (25.5) 27 65.1 (23.4) 24 69.0 (28.5) 90 −0.5 (1.7) 59 −1.2 (1.7)
Pediatric
carrier
relative
4 69.8 (17.0) 4 70.3 (10.7) 4 75.3 (24.5) 6 −1.5 (1.7) 5 −1.8 (1.3)
Adult
carrier
relative
14 71.8 (19.7) 13 70.5 (15.7) 2 80.5 (50.2) 24 −0.3 (1.3) 19 −0.9 (1.4)
Noncarrier 12 98.6 (14.6) 12 100.0 (15.7) 3 119.0 (3.0) 12 0.3 (1.5) 10 −0.3 (0.8)
United States
Proband
carrier
51 72.0 (21.1) 50 73.2 (21.0) 48 75.3 (25.8) 76 −0.02 (1.3) 76 −0.7 (1.6)
Pediatric
carrier
relative
16 85.3 (18.5) 16 85.8 (16.0) 16 86.7 (22.8) 15 0.3 (0.9) 17 −0.6 (1.5)
Adult
carrier
relative
39 99.7 (14.7) 40 99.4 (16.3) 39 99.4 (13.1) 42 0.6 (1.1) 42 −0.8 (1.5)
Noncarrier 88 106.5 (16.4) 90 107.6 (17.3) 88 104.5 (15.6) 86 0.8 (1.2) 87 0.3 (1.2)
16p11.2 Deletion
European
Proband
carrier
47 69.4 (15.1) 47 77.9 (13.7) 40 70.4 (15.2) 162 1.8 (2.4) 119 0.6 (1.5)
Pediatric
carrier
relative
15 69.8 (13.6) 15 77.9 (13.2) 15 69.7 (15.6) 19 1.4 (1.6) 14 0.03 (1.1)
Adult
carrier
relative
15 73.9 (17.2) 17 74.8 (14.2) 7 78.4 (15.1) 30 2.2 (1.8) 24 1.0 (1.4)
Noncarrier 31 94.7 (17.3) 31 96.9 (16.8) 19 91.2 (21.8) 32 0.5 (1.0) 30 −0.5 (1.2)
United States
Proband
carrier
106 81.8 (16.1) 110 86.5 (16.8) 106 77.6 (19.1) 129 1.0 (1.4) 140 1.0 (1.5)
Pediatric
carrier
relative
7 82.9 (13.6) 7 87.3 (12.7) 7 80.6 (17.7) 11 1.1 (1.1) 10 1.6 (1.6)
Adult
carrier
relative
10 86.8 (15.9) 9 94.3 (8.5) 9 88.3 (18.7) 10 2.1 (1.1) 10 0.5 (0.8)
Noncarrier 211 109.5 (12.3) 211 110.6 (13.0) 211 106.6 (12.4) 203 1.0 (1.0) 209 0.4 (1.3)
Abbreviations: BMI, bodymass index; FSIQ, Full-Scale IQ; HC, head circumference; NVIQ, Nonverbal IQ; VIQ, Verbal IQ.
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quencyofepilepsywassimilar,with69of317probands (21.8%)
and 4 of 73 relatives (5.5%) (P = .56 and P = .39, respectively).
The clinical spectrumwasbroad,with apredominanceof gen-
eralized seizures (eTable 13 in the Supplement).
In a subset of86duplication carrierswithamagnetic reso-
nance image of the brain, enlarged ventricles and cerebellar
hypoplasiawere themost frequent findings (13 [15.1%] and 10
[11.6%], respectively). In deletion carriers, posterior fossa ab-
normalitieswereobservedmost frequently (36of 108 [33.3%]),
along with Chiari type I malformations (11 of 36 [30.6%])
(eResults and eTables 12 and 13 in the Supplement).
The median age at first walking was delayed in 82 dupli-
cation proband carriers compared with 164 reciprocal dele-
tionprobandcarriers (18vs 16months;Wilcoxonranksumtest,
P = .009). This differencewasmainly driven by the increased
proportion (2.6-fold) of very-late-onsetwalking (>24months)
among the duplication probands comparedwith the deletion
probands (P = .02) (eFigure 5 in the Supplement).
Psychiatric Symptoms
Diagnostic criteria for ASD were met in 36 of 180 duplication
probands (20.0%) and 2 of 90 of their carrier relatives (2.2%).
In the deletion group, the proportion of probands with a
diagnosis of ASDwas similar (51 of 317 [16.1%]; P = .27). How-
ever, among those with an ASD diagnosis, duplication pro-
bands were significantly more impaired in cognition than
deletion probands by 26.3 points (2-sided unpaired t test,
P < .001). Duplication probands with ASD also had signifi-
cantly lower cognition than those without an ASD diagnosis
(mean FSIQ, 52.8 vs 75.4; t test, P < .001; Figure 1E). Other
DSM-IVdiagnoseswere reported in25of 38ofduplication car-
riers with ASD (65.8%), 71 of 143 probands (49.7%), and 38 of
86of their carrier relativeswithout adiagnosisofASD (44.2%).
Amongdeletion carriers, otherDSM-IV-TRdiagnoseswere re-
ported in 45 of 55 with ASD (81.8%), 157 of 266 probands
(59.0%), and 31 of 69 of their carrier relatives without ASD
(44.9%) (eTables 14and15 in theSupplement).Wedidnot iden-
tify cases of schizophrenia beyond the 4 duplication carriers
ascertained from a schizophrenia cohort.
BodyMass Index
The mean BMI z score was approximately 0.6 points lower
(P = .003) in duplication carriers comparedwith intrafamilial
controls (Table 3 andFigure 2A); this decreasewas consistent
across all carrier groups, including probands, pediatric car-
rier relatives, andadult carrier relatives (P = .004,P = .09, and
P = .01, respectively. The relative risk for obesity (BMI z score
≥2 SDs above the 98th percentile in children; BMI raw score
[calculated as weight in kilograms divided by height in me-
ters squared] ≥30 in adults) decreased 3-fold in pediatric and
adult duplication carriers when compared with the control
group (Fisher exact test, P < .001). In the reciprocal deletion
carriers, BMI z score increased by 0.7 points in carriers com-
pared with intrafamilial controls (eTable 2 in the Supple-
ment). Body mass index was not associated with ASD, sei-
zures, or NVIQ in duplications or deletions (eTables 16 and 17
in the Supplement). In the longitudinal analysis, BMI in-
creasedwithage indeletioncarriers,whereas it remained rela-
tively stable from0to−1SD induplication carriers (Figure2B).
Head Circumference
The HC z score was a mean of 1.1 points lower in duplication
carriers (P < .001; Table 3 andFigure 2C) and0.5points higher
(P = .002) in deletion carriers compared with noncarriers
(eTable 2 in the Supplement). Similar to BMI and in contrast
to IQ, this effect on HC z score was consistent across pro-
Table 3. Effect of the Duplication on Global Intelligence and Anthropometric Measures
Comparisona
FSIQ
(n = 253)
NVIQ
(n = 251)
VIQ
(n = 223)
z Score
BMI
(n = 351)
HC
(n = 314)
Estimate
P
Valueb Estimate
P
Valueb Estimate
P
Valueb Estimate
P
Valueb Estimate
P
Valueb
Fixed effects parameters
Intercept 97.5 <.001 99.9 <.001 98.3 <.001 0.4 .07 0.5 .06
Proband carrier vs noncarrier −26.3 <.001 −26.7 <.001 −24.4 <.001 −0.6 .004 −1.2 <.001
Pediatric carrier relative vs noncarrier −16.2 .001 −16.6 <.001 −15.6 .005 −0.6 .09 −1.1 .002
Adult carrier relative vs noncarrier −11.4 <.001 −14.8 <.001 −6.0 .13 −0.5 .01 −1.2 <.001
European vs US cohort −13.3 .001 −14.0 <.001 −8.4 .11 −0.7 <.001 −0.4 .06
Age, y 0.3 <.001 0.3 <.001 0.1 .05 0.02 .001 −0.001 .86
Female vs male −1.5 .42 −4.1 .04 0.6 .78 −0.1 .69 −0.2 .25
Additional contrasts
Carriera vs noncarrier −18.0 <.001 −19.3 <.001 −15.3 <.001 −0.6 .003 −1.1 <.001
Proband carrier vs pediatric carrier relative −10.1 .02 −10.1 .01 −8.8 .08 −0.01 .98 −0.1 .73
Proband carrier vs adult carrier relative −14.9 <.001 −11.9 .001 −18.4 <.001 −0.03 .87 0.1 .75
Pediatric vs adult carrier relative −4.8 .33 −1.8 .71 −9.6 .11 −0.03 .94 0.02 .96
Abbreviations: BMI, bodymass index; FSIQ, Full-Scale IQ; HC, head
circumference; NVIQ, Nonverbal IQ; VIQ, Verbal IQ.
a Carriers include proband carriers (individuals ascertained for a
neurodevelopmental disorder), pediatric carrier relatives (mostly siblings of
the probands), and adult carrier relatives (mostly transmitting parents).
b Linear mixedmodel analysis was used to estimate the effect of duplication on
FSIQ, NVIQ, VIQ, BMI z score, and HC z score.
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bands and relatives. Forty-eight of 215 duplication carriers
(22.3%) were microcephalic (HC z score, less than −2 SDs be-
low the 2th percentile). Head circumference was signifi-
cantly associated with NVIQ in duplications (P = .03) but not
deletions (P = .28), and we found a marginal association be-
tweenHC andASD in deletions (P = .07) but no association in
duplications (P = .16). Seizures were not associated with HC
in duplications or deletions (eTables 18 and 19 in the Supple-
ment). Head circumference and BMI z scores were correlated
within thedeletionandduplicationprobands (forbothgroups,
r = 0.4; P < .001). In the longitudinal analysis, the significant
decrease inHC z scores during the first 2 years of lifemirrored
the increasing HC z scores during the same period observed
indeletion carriers (Figure 2D).Malformations,medical prob-
lems, and sex differences are detailed in the eResults and
eTables 20 to 23 in the Supplement.
Discussion
We present here a comprehensive phenotypic characteriza-
tion of the 16p11.2 BP4-BP5 duplication and deletion ascer-
tained in US and European cohorts to understand their spe-
cificeffectsonneurocognitive,behavioral, andanthropometric
phenotypes. The large variance in FSIQ is an important fea-
ture of the duplication, with increased proportions of indi-
viduals at both extremes of the FSIQ distribution when com-
paredwiththedeletiongroup.Unlike thedeletiongroup,which
Figure 1. Distribution of IQMeasures in BP4-BP5 16p11.2 Duplication and Deletion Carriers and Intrafamilial Noncarrier Control Individuals
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showed a consistent effect of 16p11.2 deletion on FSIQ across
carrier groups and anormal distribution consistentwithwhat
is observed in the general population, the duplicationwas as-
sociatedwith amultimodal distribution in FSIQ anddifferent
effect sizes for probands and other carriers in the family. The
mean IQdecrement induplicationprobands (26.3 points)was
likely influenced by the clinical ascertainment for neurode-
velopmental disorders. In contrast, the 11.4-point mean de-
crease observed in adult carriers wasmost likely an underes-
timate of the duplication effect because most of these adults
are transmittingparents ascertained for higher functional sta-
tus. The mean effect of the duplication may therefore lie be-
tween these 2 estimates. Differences in IQobserved in theEu-
ropean andUS cohorts didnot influence these estimates. This
findingwasalso in agreementwith that of a recent adult popu-
lation-based study from Iceland25 that reported a 15- to 19-
point decrease in VIQ and NVIQ in 7 duplication carriers
(P = .006andP < .001, respectively).We suspect that the sub-
population of low-functioning duplication carriers with FSIQ
of 40 or less harbors additional factors that are not tolerated
and possibly lethal before birth in deletion carriers, who al-
most never present such severe cognitive impairment.
Participants with second pathogenic CNVs, other identi-
fied monogenic disorders, prematurity, fetal alcohol syn-
drome,andneonatalhypoxiawere intentionallyexcludedfrom
themain analyses, but other undetected factorsmay have in-
fluenced the severity of the clinical presentation in the pro-
bands. The2- to 3-fold increaseof additional deleteriousCNVs
in duplication compared with deletion probands ascertained
for neurodevelopmental disorders suggests that the duplica-
tion requires additional factors to reach the threshold for clini-
cal evaluation compared with the deletion. Some of these
Figure 2. BodyMass Index (BMI) and Head Circumference (HC) z Scores in Deletion and Duplication Carriers
and Intrafamilial Control Individuals
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unknowngenetic factorsmaybe inherited fromparentsas sug-
gested by the correlation between FSIQ in probands and their
parents (r = 0.4, similar to previously published studies esti-
mating theheritabilityof IQ in thegeneralpopulation26,27).The
remainingunexplainedvariationwas substantial,making the
use of parental IQ alone as a predictor insufficient (eFigure 4
in the Supplement). The significant decrease in IQ in pro-
bands with an inherited vs a de novo deletion confirmed our
hypothesis that familieswith an inheriteddeletionmaybeen-
riched inadditionalgeneticorenvironmental factors thataffect
cognition.Wedidnot observe this phenomenon for inherited
duplications.
Differences in theEuropeanvsUScohortsmaybe the con-
sequence of access to clinical chromosome microarrays that
differ by health care system. Recruitment methods also dif-
fered inbothcohorts.Probands fromtheEuropeancohortwere
directly referred from genetic units to the research center,
whereas the Simons VIP participants required active partici-
pation of the proband’s family. Nonetheless, these differ-
ences between cohorts did not influence the effect of the
duplication on IQ.
The frequency of ASD was similar in deletion and dupli-
cation probands and was consistent with previous case-
control association studies28-30 that have demonstrated that
both reciprocalCNVsequallypredispose toASD.However, our
study suggests that the duplication is associated with a form
of low-functioning ASD, whereas cognition in deletion carri-
ers with ASD is mostly within the normal range. This finding
also applies in epilepsy, equally frequent in duplication and
deletion probands but only associatedwith lower FSIQ in the
duplication group. This finding suggests that theseneuropsy-
chiatric diagnosesmayoccur in thepresenceof additional fac-
torswith anegative effect on IQ. Similar toASDcohorts, an ex-
cess of male participants and lower IQ in female participants
were observed in the duplication and deletion carriers ascer-
tained for neurodevelopmental disorders.
The low frequencyof schizophrenia in theduplication co-
hort is discordant with the association reported in prior
studies.4 This discordance is likely in part owing to the youth
of our participants (mean ages, 18.2 years in the US and 26.7
years in the European cohorts) and the fact that adults were
ascertained as parents. Following up our probands is
required to estimate the risk for schizophrenia accurately.
Although the penetrance of obesity is higher in the dele-
tion group comparedwith being underweight in the duplica-
tion group, the effect sizes of both variants appear to be simi-
lar when compared with intrafamilial controls. The effect of
the duplication mirrors that of the deletion with the excep-
tion of the age-related effect.5 As expected, geographic loca-
tion influences BMI, but the effect of the duplication is simi-
lar in both cohorts.
The 1-point decrease in mean HC z score in duplication
carriers occursduring the first twoyears of life andmirrors the
early increased growth observed in the deletion carriers
(Figure 2D). Head circumference, which is highly correlated
with brain volume,7,8 is associated with NVIQ in the duplica-
tion carriers (albeit with a small effect size) and a trend was
observed for ASD in deletion carriers. The main limitation of
this study is the ascertainment bias in the probands who
came to clinical attention and underwent clinical testing with
a chromosome microarray. We attempted to minimize this
bias by performing cascade genetic testing within families to
identify additional duplication carriers and include all dupli-
cations carriers within the study.
Conclusions
The 16p11.2 duplication has a consistent effect on some
traits, such asHC andBMI. The duplicationmay interactwith
additional factors that lead to different severities of neurobe-
havioral phenotypes, including a subgroup of low-
functioning duplication carriers with ASD, which is absent in
the deletion group. The estimated effect size of the duplica-
tion on IQ suggests that this CNV contributes to approxi-
matelyhalfof thecognitivedeficit incarrierswithmild tomod-
erate intellectual disability. Additional factorsmay contribute
to theneurodevelopmental outcome in some individuals. Fu-
ture studies will aim to quantify the contribution of addi-
tional genetic and environmental factors to the phenotype.
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